The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide.
 
Anne Bellon
Employment - Debiopharm Group
 
Valentina Gambardella
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amcure (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Alejandro Navarro
Consulting or Advisory Role - Adium Pharma; Amgen; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Eczacibasi; Pfizer; Takeda
Speakers' Bureau - AstraZeneca Spain; Roche
Expert Testimony - Hengenix; Medsir; Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Prantesh Jain
Employment - Athenex (I)
Consulting or Advisory Role - Amgen; Boehringer Ingelheim
Research Funding - Debiopharm Group (Inst); Harpoon therapeutics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson/Janssen (Inst); SOPHiA Genetics (Inst); Torl Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in Small Cell Lung Cancer (SCLC) US Patent Application No. 63/212,263; Computer extracted features from baseline CT scans predicts response to platinum-based chemotheraphy and is prognostic of overall survival in small cell lung cancer (SCLC) US Patent Application No. 63/212,247
 
José López-Picazo
Honoraria - Bristol-Myers Squibb; Roche
 
Maria J. de Miguel
Honoraria - HiFiBiO Therapeutics; MSD Oncology; PharmaMar
Travel, Accommodations, Expenses - Lilly
(OPTIONAL) Uncompensated Relationships - Abbvie; Abbvie; Array BioPharma; Genmab; HiFiBiO Therapeutics; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Salubris Biotherapeutics; Sanofi; Seagen; SERVIER
 
Shirish Gadgeel
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avistone Biotechnology (Inst); Bayer (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GRAIL (Inst); Helsinn Therapeutics (Inst); Incyte (Inst); InventisBio (Inst); Iovance Biotherapeutics (Inst); Jacobio (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Kymera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nimbus Therapeutics (Inst); Novita Pharmaceuticals (Inst); Numab (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Tango Therapeutics (Inst); Turning Point Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Merck; Mirati Therapeutics
Other Relationship - AstraZeneca
 
Sajjad Bhatti
Consulting or Advisory Role - G1 Therapeutics
 
Pedro Rocha
Travel, Accommodations, Expenses - AstraZeneca; BMS; Kyowa Kirin International; MSD; Roche
 
Alice Ke
Employment - Certara USA Inc dba Certara
Stock and Other Ownership Interests - Certara USA Inc dba Certara
 
Frederic Massiere
Employment - Debiopharm International S.A.
 
Esteban Rodrigo Imedio
Employment - Debiopharm Group
Patents, Royalties, Other Intellectual Property - Patents from Debio 0123 from Debiopharm International
 
Vito Dozio
Employment - Debiopharm Group